Table 2.
Variability Measure | Variability (Continuous, Per 3 mL/min/1.73 m2 Difference in SDa) | Variability (Tertiles) |
||
---|---|---|---|---|
T1 | T2 | T3 | ||
A. DFS, N | 12,549 | 4,183 | 4,183 | 4,183 |
Variability range | -- | 0.01-3.07 | 3.07-5.85 | 5.85-52.00 |
Number of events | 838 | 254 | 272 | 312 |
Event rate per 1,000 person-y | 25.3 | 22.3 | 24.9 | 28.8 |
HR (95% CI) | ||||
Model 1 | 1.09 (1.04-1.16) | REF | 1.13 (0.95-1.34) | 1.32 (1.12-1.55) |
Model 2 | 1.12 (1.05-1.18) | REF | 1.10 (0.93-1.31) | 1.36 (1.15-1.60) |
Model 3 | 1.11 (1.05-1.17) | REF | 1.12 (0.94-1.33) | 1.35 (1.14-1.59) |
B. CVD, N | 12,452 | 4,151 | 4,150 | 4,151 |
Variability range | -- | 0.01-3.07 | 3.07-5.85 | 5.85-52.00 |
Number of events | 379 | 110 | 130 | 139 |
Event rate per 1,000 person-y | 11.7 | 9.8 | 12.1 | 13.1 |
HR (95% CI) | ||||
Model 1 | 1.08 (1.00-1.17) | REF | 1.24 (0.96-1.60) | 1.35 (1.05-1.73) |
Model 2 | 1.11 (1.02-1.20) | REF | 1.22 (0.95-1.58) | 1.42 (1.11-1.83) |
Model 3 | 1.09 (1.01-1.19) | REF | 1.19 (0.92-1.54) | 1.37 (1.06-1.77) |
Note: Model 1: unadjusted. Model 2: adjusted for age, sex, and race/ethnicity. Model 3: includes model 2 adjustments and randomized arm (aspirin vs placebo), BMI, mean eGFR (BL-AV2), mean ACR (BL-AV2), diabetes, baseline frailty, smoking status, total cholesterol, LDL, mean SBP (BL-AV2), ACEi/ARB use, and diuretic use.
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ACR, albumin-creatinine ratio; ARB, angiotensin receptor blocker; BL-AV2, baseline to annual visit 2; BMI, body mass index; CI, confidence interval; CVD, cardiovascular disease; DFS, disability-free survival; eGFR, estimated glomerular filtration rate; HR, hazard ratio; LDL, low-density lipoprotein; REF, reference; SD, standard deviation.
A difference of 3 mL/min/1.73 m2 is approximately the difference between tertile cut-offs and allows for easier comparison between hazard ratios.